H. Kantarjian

New England Journal of Medicine · 2000–2022

A researcher in the Science corpus: 61 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Whom H. Kantarjian trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Peter A. Jones
2. Brian J. Druker
3. S. Baylin
4. M. Baccarani

Who trusts H. Kantarjian overall

1. Brian J. Druker
2. J. Cortes
3. M. Baccarani
4. Carlo Stresemann
5. J. Melo
6. T. Fry

Papers from H. Kantarjian's perspective

Ordered by how strongly the researchers H. Kantarjian trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (Blood)
4. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
6. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
7. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
8. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
9. Genomic Classification and Prognosis in Acute Myeloid Leukemia (New England Journal of Medicine)
10. The World Health Organization (WHO) classification of the myeloid neoplasms. (Blood)

Their papers

• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) — 5,221 citations
• Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. (2010) — 678 citations
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. (2004) — 825 citations
• Decitabine improves patient outcomes in myelodysplastic syndromes (2006) — 1,571 citations
• MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. (2008) — 681 citations
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007) — 718 citations
• Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. (2010) — 820 citations
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) — 3,492 citations
• Acute myeloid leukemia: current progress and future directions (2021) — 655 citations
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) — 1,281 citations
• Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. (2019) — 1,605 citations
• Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML (2018) — 1,277 citations
• The Financial Burden and Distress of Patients with Cancer: Understanding and Stepping-Up Action on the Financial Toxicity of Cancer Treatment (2018) — 816 citations
• Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. (2018) — 618 citations
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017) — 1,352 citations
• Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia (2017) — 1,744 citations
• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) — 1,052 citations
• Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia (2016) — 900 citations
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016) — 852 citations
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (2016) — 1,177 citations